{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:33:51Z","timestamp":1790249631917,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00115-025-01850-6","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:27:49Z","timestamp":1749713269000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nutzen und Risiken von Gabapentinoiden in der Gerontopsychiatrie","Benefits and risks of gabapentinoids in geriatric psychiatry"],"prefix":"10.1007","volume":"97","author":[{"given":"Maximilian","family":"Gahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"1850_CR1","volume-title":"Information zu Gabapentin und Pregabalin: Berichterstattung in den Medien zu Todesf\u00e4llen","author":"Arzneimittekommission der deutschen \u00c4rzteschaft","year":"2024","unstructured":"Arzneimittekommission der deutschen \u00c4rzteschaft (2024) Information zu Gabapentin und Pregabalin: Berichterstattung in den Medien zu Todesf\u00e4llen (Drug Safety Mail 2024\u201312)"},{"key":"1850_CR2","volume-title":"S3-Leitlinie Demenzen (Living Guideline)","author":"DGN e.\u202fV.","year":"2023","unstructured":"DGN e.\u202fV., DGPPN e.\u202fV. (2023) S3-Leitlinie Demenzen (Living Guideline) (Version: 4.0, AWMF-Register Nr. 038-013)"},{"key":"1850_CR3","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2147\/JPR.S221579","volume":"12","author":"C Bantel","year":"2019","unstructured":"Bantel\u00a0C, Hoffmann\u00a0F, Jobski\u00a0K (2019) Pain and the use of gabapentinoids in German nursing home residents\u2014results from an analysis based on statutory health insurance data. J\u00a0Pain Res 12:3175\u20133184","journal-title":"J Pain Res"},{"key":"1850_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader\u00a0HN, Wesche\u00a0D, Miller\u00a0R et\u00a0al (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661\u2013669","journal-title":"Clin Pharmacokinet"},{"key":"1850_CR5","first-page":"199","volume":"30","author":"U Bonnet","year":"2023","unstructured":"Bonnet\u00a0U (2023) Gabapentinoide \u2013 Densensitierer und GABA-Mimetika. Psychopharmakotherapie 30:199\u2013205","journal-title":"Psychopharmakotherapie"},{"key":"1850_CR6","doi-asserted-by":"publisher","first-page":"e2822","DOI":"10.1002\/hup.2822","volume":"37","author":"U Bonnet","year":"2022","unstructured":"Bonnet\u00a0U, Mcanally\u00a0HB (2022) How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z\u2011hypnotic drugs. Hum Psychopharmacol 37:e2822","journal-title":"Hum Psychopharmacol"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","volume":"27","author":"U Bonnet","year":"2017","unstructured":"Bonnet\u00a0U, Scherbaum\u00a0N (2017) How addictive are gabapentin and pregabalin? A\u00a0systematic review. Eur Neuropsychopharmacol 27:1185\u20131215","journal-title":"Eur Neuropsychopharmacol"},{"key":"1850_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1185\/03007995.2012.684044","volume":"28","author":"J Cabrera","year":"2012","unstructured":"Cabrera\u00a0J, Emir\u00a0B, Dills\u00a0D et\u00a0al (2012) Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 28:1027\u20131037","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1850_CR9","first-page":"I6","volume":"82","author":"ASJ Calkins","year":"2014","unstructured":"Calkins\u00a0ASJ, Jaros\u00a0M, Kim\u00a0R, Shang\u00a0G (2014) Peripheral edema and weight gain in adult patients with painful diabetic peripheral neuropathy (DPN) receiving gabapentin enacarbil (Gen) or pregabalin enrolled in a\u00a0randomized phase\u00a02 trial (I6\u20111.004). Neurology 82(10):I6\u20131004","journal-title":"Neurology"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/08919887241289533","volume":"38","author":"A Chen","year":"2025","unstructured":"Chen\u00a0A, Metzger\u00a0E, Lee\u00a0S et\u00a0al (2025) A proposed algorithm for the pharmacological treatment of generalized anxiety disorder in the older patient. J\u00a0Geriatr Psychiatry Neurol 38:155\u2013171","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1850_CR11","doi-asserted-by":"publisher","first-page":"e1003921","DOI":"10.1371\/journal.pmed.1003921","volume":"19","author":"C Chen","year":"2022","unstructured":"Chen\u00a0C, Winterstein\u00a0AG, Lo-Ciganic\u00a0WH et\u00a0al (2022) Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US medicare beneficiaries with chronic noncancer pain: a\u00a0population-based cohort study. PLoS Med 19:e1003921","journal-title":"PLoS Med"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","volume":"14","author":"M Chincholkar","year":"2020","unstructured":"Chincholkar\u00a0M (2020) Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain 14:104\u2013114","journal-title":"Br J Pain"},{"key":"1850_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-025-01155-6","author":"A Coin","year":"2025","unstructured":"Coin\u00a0A, Brew-Girard\u00a0E, Tracey\u00a0E et\u00a0al (2025) Management of behavioural and psychological symptoms of dementia: a\u00a0pragmatic scoping review of European guidelines and literature. Eur Geriatr Med. https:\/\/doi.org\/10.1007\/s41999-025-01155-6","journal-title":"Eur Geriatr Med"},{"key":"1850_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0269881117744996","volume":"32","author":"SJ Davies","year":"2018","unstructured":"Davies\u00a0SJ, Burhan\u00a0AM, Kim\u00a0D et\u00a0al (2018) Sequential drug treatment algorithm for agitation and aggression in Alzheimer\u2019s and mixed dementia. J\u00a0Psychopharmacol 32:509\u2013523","journal-title":"J Psychopharmacol"},{"key":"1850_CR15","first-page":"CD007076","volume":"1","author":"S Derry","year":"2019","unstructured":"Derry\u00a0S, Bell\u00a0RF, Straube\u00a0S et\u00a0al (2019) Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 1:CD7076","journal-title":"Cochrane Database Syst Rev"},{"key":"1850_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy\u00a0KE, Morrison\u00a0MD, Saklad\u00a0SR (2017) Abuse and misuse of pregabalin and gabapentin. Drugs 77:403\u2013426","journal-title":"Drugs"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","volume":"271","author":"NS Gee","year":"1996","unstructured":"Gee\u00a0NS, Brown\u00a0JP, Dissanayake\u00a0VU et\u00a0al (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a\u00a0calcium channel. J\u00a0Biol Chem 271:5768\u20135776","journal-title":"J Biol Chem"},{"key":"1850_CR18","volume-title":"Fachinformation Gabapentin Glenmark 600\u202fmg \/ 800\u202fmg Filmtabletten","author":"Glenmark Arzneimittel Gmbh","year":"2024","unstructured":"Glenmark Arzneimittel Gmbh (2024) Fachinformation Gabapentin Glenmark 600\u202fmg \/ 800\u202fmg Filmtabletten"},{"key":"1850_CR19","volume-title":"Fachinformation Lyrica Hartkapseln","author":"Viatris Healthcare Gmbh","year":"2024","unstructured":"Viatris Healthcare Gmbh (2024) Fachinformation Lyrica Hartkapseln"},{"key":"1850_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/jgs.18161","volume":"71","author":"ME Growdon","year":"2023","unstructured":"Growdon\u00a0ME, Gan\u00a0S, Yaffe\u00a0K et\u00a0al (2023) New psychotropic medication use among medicare beneficiaries with dementia after hospital discharge. J\u00a0Am Geriatr Soc 71:1134\u20131144","journal-title":"J Am Geriatr Soc"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40266-013-0126-4","volume":"30","author":"A Gupta","year":"2013","unstructured":"Gupta\u00a0A, Li\u00a0S (2013) Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75\u00a0years and over. Drugs Aging 30:999\u20131008","journal-title":"Drugs Aging"},{"key":"1850_CR22","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1073\/pnas.0708930105","volume":"105","author":"J Hendrich","year":"2008","unstructured":"Hendrich\u00a0J, Van Minh\u00a0AT, Heblich\u00a0F et\u00a0al (2008) Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S\u00a0A 105:3628\u20133633","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"1128601","DOI":"10.3389\/fphar.2023.1128601","volume":"14","author":"YH Huang","year":"2023","unstructured":"Huang\u00a0YH, Pan\u00a0MH, Yang\u00a0HI (2023) The association between gabapentin or pregabalin use and the risk of dementia: an analysis of the national health insurance research database in Taiwan. Front Pharmacol 14:1128601","journal-title":"Front Pharmacol"},{"key":"1850_CR24","doi-asserted-by":"publisher","first-page":"d4065","DOI":"10.1136\/bmj.d4065","volume":"343","author":"BS Husebo","year":"2011","unstructured":"Husebo\u00a0BS, Ballard\u00a0C, Sandvik\u00a0R et\u00a0al (2011) Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 343:d4065","journal-title":"BMJ"},{"key":"1850_CR25","doi-asserted-by":"publisher","first-page":"e70014","DOI":"10.1002\/gps.70014","volume":"39","author":"K Ishtiak-Ahmed","year":"2024","unstructured":"Ishtiak-Ahmed\u00a0K, Jensen-Dahm\u00a0C, Christensen\u00a0KS et\u00a0al (2024) Association of psychotropic prescriptions with non-registered indications and the risk of mortality in older adults: a\u00a0Danish nationwide cohort study. Int J Geriatr Psychiatry 39:e70014","journal-title":"Int J Geriatr Psychiatry"},{"key":"1850_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00002512-200825030-00002","volume":"25","author":"Y Kim","year":"2008","unstructured":"Kim\u00a0Y, Wilkins\u00a0KM, Tampi\u00a0RR (2008) Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a\u00a0review of the evidence. Drugs Aging 25:187\u2013196","journal-title":"Drugs Aging"},{"key":"1850_CR27","doi-asserted-by":"publisher","first-page":"e2444488","DOI":"10.1001\/jamanetworkopen.2024.44488","volume":"7","author":"MTY Leung","year":"2024","unstructured":"Leung\u00a0MTY, Turner\u00a0JP, Marquina\u00a0C et\u00a0al (2024) Gabapentinoids and risk of hip fracture. JAMA Netw Open 7:e2444488","journal-title":"JAMA Netw Open"},{"key":"1850_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2448833","author":"J Li","year":"2025","unstructured":"Li\u00a0J, Dai\u00a0Z, Zhang\u00a0Z et\u00a0al (2025) Gabapentinoids related psychiatric disorders: an analysis based on the FAERS database from 2004 to 2023. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2448833","journal-title":"Expert Opin Drug Saf"},{"key":"1850_CR29","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/acn3.51372","volume":"8","author":"J Li","year":"2021","unstructured":"Li\u00a0J, Song\u00a0G, Jin\u00a0Q et\u00a0al (2021) The alpha2delta-1\/NMDA receptor complex is involved in brain injury after intracerebral hemorrhage in mice. Ann Clin Transl Neurol 8:1366\u20131375","journal-title":"Ann Clin Transl Neurol"},{"key":"1850_CR30","series-title":"Arzneiverordnungs-Report 2023","volume-title":"Epilepsien","year":"2023","unstructured":"Ludwig\u00a0WD, M\u00fchlbauer\u00a0B, Seifert\u00a0R (Hrsg) (2023) Epilepsien. Arzneiverordnungs-Report 2023. Springer, Berlin"},{"key":"1850_CR31","doi-asserted-by":"publisher","first-page":"1460325","DOI":"10.3389\/fnins.2024.1460325","volume":"18","author":"L Maleki","year":"2024","unstructured":"Maleki\u00a0L, Mohammadian\u00a0F, Panahishokouh\u00a0M et\u00a0al (2024) A randomized, double-blind, placebo-controlled clinical trial to evaluate pregabalin efficacy in the treatment of behavioral and psychological symptoms of dementia in patients with Alzheimer\u2019s disease. Front Neurosci 18:1460325","journal-title":"Front Neurosci"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2021.1195","volume":"325","author":"DT Maust","year":"2021","unstructured":"Maust\u00a0DT, Strominger\u00a0J, Kim\u00a0HM et\u00a0al (2021) Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US. JAMA 325:952\u2013961","journal-title":"JAMA"},{"key":"1850_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1192\/bjp.bp.107.037788","volume":"193","author":"S Montgomery","year":"2008","unstructured":"Montgomery\u00a0S, Chatamra\u00a0K, Pauer\u00a0L et\u00a0al (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389\u2013394","journal-title":"Br J Psychiatry"},{"key":"1850_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.ajkd.2021.11.007","volume":"80","author":"FT Muanda","year":"2022","unstructured":"Muanda\u00a0FT, Weir\u00a0MA, Ahmadi\u00a0F et\u00a0al (2022) Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: a\u00a0population-based cohort study. Am J Kidney Dis 80:98\u2013107.e1","journal-title":"Am J Kidney Dis"},{"key":"1850_CR35","doi-asserted-by":"publisher","first-page":"910719","DOI":"10.3389\/fphar.2022.910719","volume":"13","author":"G Oh","year":"2022","unstructured":"Oh\u00a0G, Moga\u00a0DC, Fardo\u00a0DW et\u00a0al (2022) The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition. Front Pharmacol 13:910719","journal-title":"Front Pharmacol"},{"key":"1850_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bcp.15532","volume":"89","author":"GY Oh","year":"2023","unstructured":"Oh\u00a0GY, Moga\u00a0DC, Abner\u00a0EL (2023) Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer\u2019s Coordinating Center (2006\u20132019). Br J Clin Pharmacol 89:410\u2013415","journal-title":"Br J Clin Pharmacol"},{"key":"1850_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40264-018-0695-6","volume":"41","author":"L Ortiz De Landaluce","year":"2018","unstructured":"Ortiz De Landaluce\u00a0L, Carbonell\u00a0P, Asensio\u00a0C et\u00a0al (2018) Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a\u00a0population-based cohort study in an electronic prescription database. Drug Saf 41:1325\u20131331","journal-title":"Drug Saf"},{"key":"1850_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-180594","volume":"66","author":"T Sarycheva","year":"2018","unstructured":"Sarycheva\u00a0T, Taipale\u00a0H, Lavikainen\u00a0P et\u00a0al (2018) Incidence and prevalence of antiepileptic medication use in community-dwelling persons with and without Alzheimer\u2019s disease. J\u00a0Alzheimers Dis 66:387\u2013395","journal-title":"J Alzheimers Dis"},{"key":"1850_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"F Schifano","year":"2014","unstructured":"Schifano\u00a0F (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28:491\u2013496","journal-title":"CNS Drugs"},{"key":"1850_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12916-024-03774-5","volume":"22","author":"IC Scott","year":"2024","unstructured":"Scott\u00a0IC, Daud\u00a0N, Bailey\u00a0J et\u00a0al (2024) Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the clinical practice research datalink aurum. BMC Med 22:575","journal-title":"BMC Med"},{"key":"1850_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/JCP.0000000000001203","volume":"40","author":"K Segers","year":"2020","unstructured":"Segers\u00a0K, Baxevani\u00a0E, Benoit\u00a0F et\u00a0al (2020) Pregabalin as a\u00a0treatment for anxiety in patients with dementia with Lewy bodies: a\u00a0case series. J\u00a0Clin Psychopharmacol 40:297\u2013299","journal-title":"J Clin Psychopharmacol"},{"key":"1850_CR42","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/jgs.14897","volume":"65","author":"TP Semla","year":"2017","unstructured":"Semla\u00a0TP, Lee\u00a0A, Gurrera\u00a0R et\u00a0al (2017) Off-label prescribing of second-generation antipsychotics to elderly veterans with posttraumatic stress disorder and dementia. J\u00a0Am Geriatr Soc 65:1789\u20131795","journal-title":"J Am Geriatr Soc"},{"key":"1850_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"Stinton\u00a0C, Mckeith\u00a0I, Taylor\u00a0JP et\u00a0al (2015) Pharmacological management of Lewy body dementia: a\u00a0systematic review and meta-analysis. Am J Psychiatry 172:731\u2013742","journal-title":"Am J Psychiatry"},{"key":"1850_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bcp.13844","volume":"85","author":"T Supasitthumrong","year":"2019","unstructured":"Supasitthumrong\u00a0T, Bolea-Alamanac\u00a0BM, Asmer\u00a0S et\u00a0al (2019) Gabapentin and pregabalin to treat aggressivity in dementia: a\u00a0systematic review and illustrative case report. Br J Clin Pharmacol 85:690\u2013703","journal-title":"Br J Clin Pharmacol"},{"key":"1850_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JAD-180912","volume":"68","author":"H Taipale","year":"2019","unstructured":"Taipale\u00a0H, Lampela\u00a0P, Koponen\u00a0M et\u00a0al (2019) Antiepileptic drug use is associated with an increased risk of pneumonia among community-dwelling persons with Alzheimer\u2019s disease-matched cohort study. J\u00a0Alzheimers Dis 68:127\u2013136","journal-title":"J Alzheimers Dis"},{"key":"1850_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"CP Taylor","year":"2007","unstructured":"Taylor\u00a0CP, Angelotti\u00a0T, Fauman\u00a0E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a\u00a0target for antiepileptic drug discovery. Epilepsy Res 73:137\u2013150","journal-title":"Epilepsy Res"},{"key":"1850_CR47","first-page":"CD007938","volume":"6","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen\u00a0PJ, Derry\u00a0S, Bell\u00a0RF et\u00a0al (2017) Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 6:CD7938","journal-title":"Cochrane Database Syst Rev"},{"key":"1850_CR48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","volume":"52","author":"G Zaccara","year":"2011","unstructured":"Zaccara\u00a0G, Gangemi\u00a0P, Perucca\u00a0P et\u00a0al (2011) The adverse event profile of pregabalin: a\u00a0systematic review and meta-analysis of randomized controlled trials. Epilepsia 52:826\u2013836","journal-title":"Epilepsia"},{"key":"1850_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40266-019-00732-2","volume":"37","author":"D Zhao","year":"2020","unstructured":"Zhao\u00a0D, Shridharmurthy\u00a0D, Alcusky\u00a0MJ et\u00a0al (2020) The prevalence and factors associated with antiepileptic drug use in US nursing home residents. Drugs Aging 37:137\u2013145","journal-title":"Drugs Aging"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01850-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:03:25Z","timestamp":1778681005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-025-01850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s00115-025-01850-6","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"13 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Gahr gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}